Solid form screening--a review.
暂无分享,去创建一个
Jukka Rantanen | Jaakko Aaltonen | Vishal Koradia | Morten Allesø | Sabiruddin Mirza | Keith C Gordon | J. Rantanen | Sabiruddin Mirza | K. Gordon | M. Allesø | V. Koradia | J. Aaltonen | Morten Allesø
[1] K. Shankland,et al. Control and prediction of packing motifs: a rare occurrence of carbamazepine in a catemeric configuration , 2006 .
[2] Orn Almarsson,et al. Salt Selection and Simultaneous Polymorphism Assessment via High-Throughput Crystallization: The Case of Sertraline , 2003 .
[3] R. Davey,et al. Hydration in molecular crystals: A Cambridge structural database analysis , 2003 .
[4] T. Threlfall. Analysis of organic polymorphs. A review , 1995 .
[5] Y. Ozaki,et al. Comparative determination of polymorphs of indomethacin in powders and tablets by chemometrical near-infrared spectroscopy and X-ray powder diffractometry , 2003, AAPS PharmSciTech.
[6] E. Boldyreva,et al. Effect of High Pressure on the Polymorphs of Paracetamol , 2002 .
[7] A. Matzger,et al. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. , 2003, Journal of pharmaceutical sciences.
[8] Jeremy I. Bulow,et al. The Gaming of Pharmaceutical Patents , 2003, Innovation Policy and the Economy.
[9] D. Grant,et al. Polymorph screening: influence of solvents on the rate of solvent-mediated polymorphic transformation. , 2001, Journal of pharmaceutical sciences.
[10] K. Kachrimanis,et al. Effects of harvesting and cooling on crystallization and transformation of orthorhombic paracetamol in ethanolic solution. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[11] K. Morris. STRUCTURAL ASPECTS OF HYDRATES AND SOLVATES , 1999 .
[12] Eric R. Ziegel,et al. Handbook of Chemometrics and Qualimetrics, Part B , 2000, Technometrics.
[13] Bruno C. Hancock,et al. Characteristics and significance of the amorphous state in pharmaceutical systems. , 1997, Journal of pharmaceutical sciences.
[14] D. Grant. THEORY AND ORIGIN OF POLYMORPHISM , 1999 .
[15] G. P. Stahly. Diversity in Single- and Multiple-Component Crystals. The Search for and Prevalence of Polymorphs and Cocrystals , 2007 .
[16] T. C. Lewis,et al. The polymorphism of progesterone: stabilization of a 'disappearing' polymorph by co-crystallization. , 2007, Journal of pharmaceutical sciences.
[17] Sarah L Price,et al. Crystal structure prediction of small organic molecules: a second blind test. , 2002, Acta crystallographica. Section B, Structural science.
[18] Orn Almarsson,et al. High-Throughput Surveys of Crystal Form Diversity of Highly Polymorphic Pharmaceutical Compounds , 2003 .
[19] W. Mccrone,et al. Pharmaceutical applications of polymorphism. , 1969, Journal of pharmaceutical sciences.
[20] A. Jaffe,et al. Innovation policy and the economy , 2001 .
[21] Lawrence X. Yu,et al. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). , 2004, Advanced drug delivery reviews.
[22] S. Byrn. Solid state chemistry of drugs , 1982 .
[23] M. Otsuka,et al. Comparative evaluation of the degree of indomethacin crystallinity by chemoinfometrical fourie-transformed near-infrared spectroscopy and conventional powder X-ray diffractiometry , 2000, AAPS PharmSci.
[24] Low-level determination of polymorph composition in physical mixtures by near-infrared reflectance spectroscopy. , 2001, Journal of pharmaceutical sciences.
[25] J. Senker,et al. Polymorphism in benzamide: solving a 175-year-old riddle. , 2007, Angewandte Chemie.
[26] Ronei Jesus Poppi,et al. Figures of merit for the determination of the polymorphic purity of carbamazepine by infrared spectroscopy and multivariate calibration. , 2004, Journal of pharmaceutical sciences.
[27] Changquan Calvin Sun,et al. Influence of Crystal Structure on the Tableting Properties of Sulfamerazine Polymorphs , 2001, Pharmaceutical Research.
[28] Jukka Rantanen,et al. DRIFT-IR for quantitative characterization of polymorphic composition of sulfathiazole , 2005 .
[29] Peddy Vishweshwar,et al. Pharmaceutical co-crystals. , 2006, Journal of pharmaceutical sciences.
[30] Donald E. Williams,et al. Improved intermolecular force field for molecules containing H, C, N, and O atoms, with application to nucleoside and peptide crystals , 2001, J. Comput. Chem..
[31] Paul E. Shaw,et al. Iterative high-throughput polymorphism studies on acetaminophen and an experimentally derived structure for form III. , 2002, Journal of the American Chemical Society.
[32] Barry K. Lavine,et al. Spectral Pattern Recognition Using Self-Organizing MAPS , 2004, J. Chem. Inf. Model..
[33] A. Gavezzotti. Calculation of Intermolecular Interaction Energies by Direct Numerical Integration over Electron Densities. I. Electrostatic and Polarization Energies in Molecular Crystals , 2002 .
[34] Jukka Rantanen,et al. Multivariate data analysis as a fast tool in evaluation of solid state phenomena. , 2006, Journal of pharmaceutical sciences.
[35] J. Dunitz. Are crystal structures predictable? , 2003, Chemical communications.
[36] Lawrence X. Yu,et al. Applications of process analytical technology to crystallization processes. , 2004, Advanced drug delivery reviews.
[37] Donald E. Williams. Improved intermolecular force field for crystalline oxohydrocarbons including OHO hydrogen bonding , 2001 .
[38] Joel Bernstein,et al. Polymorphism in Molecular Crystals , 2002 .
[39] Richard D. Braatz,et al. First-principles and direct design approaches for the control of pharmaceutical crystallization , 2005 .
[40] Effects of solvent composition and temperature on polymorphism and crystallization behavior of thiazole-derivative , 2002 .
[41] P Verwer,et al. A test of crystal structure prediction of small organic molecules. , 2000, Acta crystallographica. Section B, Structural science.
[42] S. Price. The computational prediction of pharmaceutical crystal structures and polymorphism. , 2004, Advanced drug delivery reviews.
[43] Claus Cornett,et al. Solvent diversity in polymorph screening. , 2008, Journal of pharmaceutical sciences.
[44] D. E. Williams,et al. Improved intermolecular force field for crystalline hydrocarbons containing four- or three-coordinated carbon , 1999 .
[45] L. Dupont,et al. Structure cristalline et moléculaire de la progestérone, C21H30O2 , 1972 .
[46] G A Stephenson,et al. Characterization of the solid state: quantitative issues. , 2001, Advanced drug delivery reviews.
[48] P. W. Cains,et al. Sonocrystallization: The Use of Ultrasound for Improved Industrial Crystallization , 2005 .
[49] S. Price,et al. An automated parallel crystallisation search for predicted crystal structures and packing motifs of carbamazepine. , 2006, Journal of pharmaceutical sciences.
[50] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[51] Lawrence X. Yu,et al. Scientific Considerations of Pharmaceutical Solid Polymorphism in Regulatory Applications , 2006 .
[52] Wolfgang Beckmann,et al. Seeding the Desired Polymorph: Background, Possibilities, Limitations, and Case Studies , 2000 .
[53] David J.W. Grant,et al. Stabilization of a metastable polymorph of sulfamerazine by structurally related additives , 2002 .
[54] Bruno C. Hancock,et al. What is the True Solubility Advantage for Amorphous Pharmaceuticals? , 2000, Pharmaceutical Research.
[55] D. E. Williams,et al. Coulombic interactions in crystalline hydrocarbons , 1974 .
[56] K. Morris,et al. Stabilization of a Metastable Polymorph of 4-Methyl-2-nitroacetanilide by Isomorphic Additives , 2001 .
[57] Paul Geladi,et al. Principal Component Analysis , 1987, Comprehensive Chemometrics.
[58] Robert Docherty,et al. Automation of Solid form Screening Procedures in the Pharmaceutical Industry—How to Avoid the Bottlenecks , 2004 .
[59] Jukka Rantanen,et al. Polymorph screening using near-infrared spectroscopy , 2003 .
[60] K. Takayama,et al. An accurate quantitative analysis of polymorphs based on artificial neural networks. , 2006, Colloids and surfaces. B, Biointerfaces.
[61] T. C. Lewis,et al. A third blind test of crystal structure prediction. , 2005, Acta crystallographica. Section B, Structural science.
[62] S. Chemburkar,et al. Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development , 2000 .
[63] M. Anttila,et al. Pharmacokinetics and dissolution of two crystalline forms of carbamazepine , 1983 .
[64] Aditya Mohan Kaushal,et al. Amorphous drug delivery systems: molecular aspects, design, and performance. , 2004, Critical reviews in therapeutic drug carrier systems.
[65] Response surface analysis of solution-mediated polymorphic transformation of buspirone hydrochloride. , 2007, Journal of pharmaceutical and biomedical analysis.
[66] P. Gemperline,et al. Near-IR Detection of Polymorphism and Process-Related Substances , 1996 .
[67] Rolf Hilfiker,et al. POLYMORPHISM , 1945 .
[68] Leonard J. Chyall,et al. New solid-state chemistry technologies to bring better drugs to market: knowledge-based decision making , 2007, Expert opinion on drug discovery.
[69] R. S. Bradley,et al. 349. The vapour pressure and lattice energy of some aromatic ring compounds , 1953 .
[70] G Nichols,et al. Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution. , 1998, Journal of pharmaceutical sciences.
[71] Yadan W. Chen,et al. Characterization and quantitation of aprepitant drug substance polymorphs by attenuated total reflectance fourier transform infrared spectroscopy. , 2003, Analytical chemistry.
[72] Kati Pöllänen,et al. Qualitative in situ analysis of multiple solid-state forms using spectroscopy and partial least squares discriminant modeling. , 2007, Journal of pharmaceutical sciences.
[73] A. Gavezzotti. A solid-state chemist's view of the crystal polymorphism of organic compounds. , 2007, Journal of pharmaceutical sciences.
[74] R. Hilfiker,et al. Approaches to Polymorphism Screening , 2006 .
[75] S. Byrn,et al. Chemical reactivity in solid-state pharmaceuticals: formulation implications. , 2001, Advanced drug delivery reviews.
[76] Jonathan M Goodman,et al. Polymorph control: past, present and future. , 2008, Drug discovery today.
[77] Y. Guo,et al. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. , 2000, Journal of pharmaceutical sciences.
[78] J. Rantanen,et al. Insight into Thermally Induced Phase Transformations of Erythromycin A Dihydrate , 2006 .
[79] Lynne S Taylor,et al. Hyphenation of Raman spectroscopy with gravimetric analysis to interrogate water-solid interactions in pharmaceutical systems. , 2007, Journal of pharmaceutical and biomedical analysis.
[80] H. Ando,et al. Analysis of known crystals to design polymorph prediction strategies. , 2007, Journal of pharmaceutical sciences.
[81] Hierarchies of Intermolecular Potentials and Forces: Progress Towards a Quantitative Evaluation , 2005 .
[82] T. Rades,et al. Determination of polymorphic forms of ranitidine-HCl by DRIFTS and XRPD. , 2001, Journal of pharmaceutical and biomedical analysis.
[83] A. Gavezzotti,et al. Computer simulations and analysis of structural and energetic features of some crystalline energetic materials. , 2007, The journal of physical chemistry. B.
[84] R. Davey,et al. Disappearing polymorphs and the role of reaction by-products: the case of sulphathiazole , 1998 .
[85] M. Mazzotti,et al. In Situ Monitoring and Modeling of the Solvent-Mediated Polymorphic Transformation of l-Glutamic Acid , 2006 .
[86] Danielle Giron,et al. Solid-state of pharmaceutical compounds , 2004 .
[87] P. Paronen,et al. Dynamic solid-state and tableting properties of four theophylline forms. , 2001, International journal of pharmaceutics.
[88] J. C. Guyot,et al. A new pure paracetamol for direct compression : the orthorhombic form. , 1996 .
[89] Michael J Cima,et al. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.
[90] M. Kitamura,et al. Controlling factor of polymorphism in crystallization process , 2002 .
[91] Thomas Rades,et al. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[92] J. Swarbrick,et al. Encyclopedia of Pharmaceutical Technology , 2006 .
[93] A. Gavezzotti. Quantitative Ranking of Crystal Packing Modes by Systematic Calculations on Potential Energies and Vibrational Amplitudes of Molecular Dimers. , 2005, Journal of chemical theory and computation.
[94] A. Gavezzotti,et al. Molecular recognition in organic crystals: directed intermolecular bonds or nonlocalized bonding? , 2005, Angewandte Chemie.
[95] Sarah L Price,et al. From crystal structure prediction to polymorph prediction: interpreting the crystal energy landscape. , 2008, Physical chemistry chemical physics : PCCP.
[96] P. Karamertzanis,et al. Racemic progesterone: predicted in silico and produced in the solid state. , 2006, Chemical communications.
[97] P. Taday,et al. Understanding the influence of polymorphism on phonon spectra: lattice dynamics calculations and terahertz spectroscopy of carbamazepine. , 2006, The journal of physical chemistry. B.
[98] Jeanette T. Dunlap,et al. A metastable polymorph of metformin hydrochloride: Isolation and characterization using capillary crystallization and thermal microscopy techniques , 2004 .
[99] Johanna Smeyers-Verbeke,et al. Handbook of Chemometrics and Qualimetrics: Part A , 1997 .
[100] W. Tong,et al. Impact of solid state properties on developability assessment of drug candidates. , 2004, Advanced drug delivery reviews.
[101] N. Redman-Furey,et al. Statistical cluster analysis of pharmaceutical solvents. , 2007, International journal of pharmaceutics.
[102] J. Mullin. Industrial techniques and equipment , 2001 .
[103] Sharmistha Datta,et al. Crystal structures of drugs: advances in determination, prediction and engineering , 2004, Nature reviews. Drug discovery.
[104] I. Miroshnyk,et al. Influence of solvents on the variety of crystalline forms of erythromycin , 2003, AAPS PharmSci.
[105] David J. Willock,et al. The relaxation of molecular crystal structures using a distributed multipole electrostatic model , 1995, J. Comput. Chem..
[106] Glen Spraggon,et al. Computational analysis of crystallization trials. , 2002, Acta crystallographica. Section D, Biological crystallography.
[107] R. Docherty,et al. Polymorphism in Molecular Crystals: Stabilization of a Metastable Form by Conformational Mimicry , 1997 .
[108] T. Rades,et al. Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride. , 1999, International journal of pharmaceutics.
[109] M. Otsuka,et al. Determination of indomethacin polymorphic contents by chemometric near-infrared spectroscopy and conventional powder X-ray diffractometry. , 2001, The Analyst.
[110] Rasmus Bro,et al. Exploring complex interactions in designed data using GEMANOVA. Color changes in fresh beef during storage , 2002 .
[111] David E. Bugay,et al. Physical Characterization of Pharmaceutical Solids , 1995, Pharmaceutical Research.
[112] L. Howard. Use of Patents in Drug Lifecycle Management , 2007 .
[113] S. L. Mayo,et al. DREIDING: A generic force field for molecular simulations , 1990 .
[114] H. Aboul‐Enein,et al. Analysis of mebendazole polymorphs by Fourier transform IR spectrometry using chemometric methods. , 2002, Biopolymers.
[115] B. Freiermuth,et al. Polymorphism - integrated approach from high-throughput screening to crystallization optimization , 2003 .
[116] Christopher T. Walsh,et al. Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.
[117] R. Davey,et al. From Molecules to Crystallizers: An Introduction to Crystallization , 2000 .
[118] B. Shekunov,et al. CRYSTALLIZATION PROCESSES IN PHARMACEUTICAL TECHNOLOGY AND DRUG DELIVERY DESIGN , 2000 .
[119] L Yu,et al. Amorphous pharmaceutical solids: preparation, characterization and stabilization. , 2001, Advanced drug delivery reviews.
[120] Jukka Rantanen,et al. Hyphenated spectroscopy as a polymorph screening tool. , 2007, Journal of pharmaceutical and biomedical analysis.
[121] G. Day,et al. Atomistic calculations of phonon frequencies and thermodynamic quantities for crystals of rigid organic molecules , 2003 .
[122] Claus Cornett,et al. Solvent subset selection for polymorph screening , 2008 .
[123] Steve Lowry,et al. Integrating a Raman Microscope into the Workflow of a High-Throughput Crystallization Laboratory , 2006 .
[124] W. Addicks,et al. Polymorphism in generic drug product development. , 2004, Advanced drug delivery reviews.
[125] J. Anwar,et al. Crystallization of polymorphs : the effect of solvent , 1993 .
[126] A. Gavezzotti,et al. Ten years of experience in polymorph prediction: what next? , 2002 .
[127] M. Kemper,et al. Quantitative analysis of polymorphs in binary and multi-component powder mixtures by near-infrared reflectance spectroscopy. , 2000, International journal of pharmaceutics.
[128] David J W Grant,et al. Identifying the Stable Polymorph Early in the Drug Discovery–Development Process , 2005, Pharmaceutical development and technology.
[129] K. Raghavan,et al. Grouping solvents by statistical analysis of solvent property parameters: implication to polymorph screening. , 2004, International journal of pharmaceutics.
[130] R. Davey. Crystallization: How come you look so good? , 2004, Nature.
[131] A. Matzger,et al. Form IV of carbamazepine. , 2002, Journal of pharmaceutical sciences.
[132] Michael J. Cima,et al. Elucidation of crystal form diversity of the HIV protease inhibitor ritonavir by high-throughput crystallization , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[133] Sarah L. Price,et al. Energy minimization of crystal structures containing flexible molecules , 2006 .
[134] J. Guillory. GENERATION OF POLYMORPHS, HYDRATES, SOLVATES, AND AMORPHOUS SOLIDS , 1999 .
[135] W. Curatolo,et al. Drug polymorphism and dosage form design: a practical perspective. , 2004, Advanced drug delivery reviews.
[136] Stephen R. Byrn,et al. Crystal structure, solid-state NMR spectra, and oxygen reactivity of five crystal forms of prednisolone tert-butylacetate , 1988 .
[137] H. Brittain. Polymorphism in Pharmaceutical Solids , 1999 .
[138] Jukka Rantanen,et al. In situ measurement of solvent-mediated phase transformations during dissolution testing. , 2006, Journal of pharmaceutical sciences.
[139] K. Gordon,et al. Quantitative analysis of polymorphic mixtures of ranitidine hydrochloride by Raman spectroscopy and principal components analysis. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[140] Thomas Rades,et al. Quantitative analysis of polymorphic mixtures of carbamazepine by Raman spectroscopy and principal components analysis , 2004 .
[141] Chemometrics Approach to the Determination of Polymorphism of a Drug Compound by Infrared Spectroscopy , 2000, Drug development and industrial pharmacy.
[142] Vinod P. Shah,et al. The Bioinequivalence of Carbamazepine Tablets with a History of Clinical Failures , 1992, Pharmaceutical Research.
[143] G. Buckton,et al. The novel combination of dynamic vapour sorption gravimetric analysis and near infra-red spectroscopy as a hyphenated technique. , 2000, International journal of pharmaceutics.